The Pharmaceutical Journal
Vol 270 No 7251 p742
31 May 2003

This article
Reprint
Photocopy

News summary

Conference summaries  24 May   31 May  

Related websites
American Thoracic Society conference 2003 (more)

Moxifloxacin better than standard

A five-day course of oral moxifloxacin (Avelox) 400mg daily produces a higher clinical cure rate for acute exacerbations of chronic bronchitis than a seven-day course of a standard antibiotic (70.9 per cent vs 62.8 per cent, P=0.05). In addition, the time until the next exacerbation was found to be longer in the moxifloxacin group than in the comparator group (131.0–132.8 days vs 103.5–118.0 days, P=0.03) and this is consistent with superior eradication of bacteria, researchers say.

The Journal attended the American Thoracic Society's 99th international conference in Seattle, Washington, courtesy of GlaxoSmithKline